So I won't be helped then? I can only hear up to 12,000 Hz so far. According to the graph, shouldn't I be able to be helped with FX-322?No can do. Cochlear implants damage the cochlea and it's highly likely PCA won't work. Deafness of a genetic cause requires a different treatment path. It appears that people with severe hearing loss wont benefit from FX-322 in its current form.
Yeah this is why my tinnitus is annoying. Everything sounds so muddled (at least in comparison to before) to the extent that I can't even properly hear rain. As a result, despite my tinnitus being objectively quieter than I think a majority of people's tinnitus, I can still hear it because my hearing has degraded to the degree that it has.- Improve hearing in areas where there are deficits, making tinnitus easier to mask.
Why would you believe that FX-345 could reach that far back but not Otonomy? How are they expecting to reach that far back?A mere claim without references is hard to believe.
The possibility that FX-345 will reach 4 kHz and have an effect must be calculated based on the data of FX-322.
Data such as gel performance and drug concentration.
I think there is a possibility of success of FX-345.
I want Otonomy to show evidence. I can't believe their gel actually penetrates the entire cochlea just because they have a patent. Why is it just a claim? Do they have evidence from clinical trials?Why would you believe that FX-345 could reach that far back but not Otonomy? How are they expecting to reach that far back?
Also for Otonomy, I believe they patented the way they were going to reach that deep so I think that counts for something. Its drug delivery is not based on the drug itself. I don't have good information on the topic so I could be wrong. Maybe you know about this and have a response?
I believe FX-322 can reach at least 8 kHz. This is due to the fact that a few of the patients in the Phase 1b trials had improvements in their audiograms at 8 kHz.Why would you believe that FX-345 could reach that far back but not Otonomy? How are they expecting to reach that far back?
Also for Otonomy, I believe they patented the way they were going to reach that deep so I think that counts for something. Its drug delivery is not based on the drug itself. I don't have good information on the topic so I could be wrong. Maybe you know about this and have a response?
Speaking of audiograms, to what degree were there improvements at 8 kHz? Is it to the level of "normal" hearing? I guess that depends on the actual amount of damage within the cochlea but I am still interested in knowing.I believe FX-322 can reach at least 8 kHz. This is due to the fact that a few of the patients in the Phase 1b trials had improvements in their audiograms at 8 kHz.
Slide P33 in October 2019.Speaking of audiograms, to what degree were there improvements at 8 kHz? Is it to the level of "normal" hearing? I guess that depends on the actual amount of damage within the cochlea but I am still interested in knowing.
Thank you for your time!Slide P33 in October 2019.
It was an improvement of 10 dB or more. In a slide created after this, probably one year later, one of the four had an improvement of 15 dB.
View attachment 48370
P22 on the same slide.
They said it would reach up to 4 kHz. 4 kHz is the area where noise first attacks and destroys hair cells. With FX-345 they aim to reach deeper than 4 kHz.
View attachment 48371
Unfortunately, I only know that it has improved by 10 dB or more. These four people seemed to be the same people with moderate hearing loss with significantly improved word recognition. It was announced that these four people had moderate hearing loss.How does this compare with normal hearing?
So does that mean "it didn't reach levels of normal hearing" or "I don't know if it reached levels of normal hearing"?Unfortunately, I only know that it has improved by 10 dB or more. These four people seemed to be the same people with moderate hearing loss with significantly improved word recognition. It was announced that these four people had moderate hearing loss.
But, I think there may be people with mild hearing loss who improve to "normal hearing" at 8 kHz, if FX-322 can be cumulatively effective with multiple injections at appropriate intervals. Even if a single injection only provides an improvement of 5 dB.
FX-322 induces an asymmetrical division of cells creating both a new hair cell and a new progenitor cell.do the progenitor cells disappear after regeneration or do they remain (so, for instance, if your regenerated hair cells got damaged, could you get the treatment again)? Because, according to the Tinnitus Talk Podcast interview, Frequency Therapeutics' approach to hair cell regeneration is to make use of progenitor cells which stem cell therapies destroys.
The most important metric I think people here are looking at is a reduction in tinnitus severity, something that neither WR scores or audiograms give us, but between the two, improved high frequency hearing would logically have a stronger correlation.I know many around here consider audiograms to be the divine trinity or the holy grail of hearing measurement but as hearing regeneration science advances, we are learning more and more about the intricacies of the inner ear and hearing.
What do you think is the reason why TFI was not published in Phase 2a?The most important metric I think people here are looking at is a reduction in tinnitus severity, something that neither WR scores or audiograms give us, but between the two, improved high frequency hearing would logically have a stronger correlation.
1.What do you think is the reason why TFI was not published in Phase 2a?
1) It really didn't work.
2) Since there were many improvements in placebo, it could not be said that it was effective in comparison.
3) There was improvement in the medication group, but because there were many improvements in placebo due to improvement in word recognition and high frequency, the reason (correlation) could not be found and they could not publish it.
4) Something else.
I doubt they are hiding good news.What do you think is the reason why TFI was not published in Phase 2a?
I feel like it could be 3.What do you think is the reason why TFI was not published in Phase 2a?
1) It really didn't work.
2) Since there were many improvements in placebo, it could not be said that it was effective in comparison.
3) There was improvement in the medication group, but because there were many improvements in placebo due to improvement in word recognition and high frequency, the reason (correlation) could not be found and they could not publish it.
4) Something else.
Wasn't that only after the initial safety trial though with a handful of patients? Since then there had been no mention of tinnitus? Or did I miss some other news?I feel like it could be 3.
We did hear some anecdotes from Carl LeBel that there were tinnitus improvements in some patients. We should know more by the end of this year with the single dose Phase 2b trial.
This was the Phase 1b trial with a single dose of FX-322 that saw some patients with lower tinnitus level so hopefully the Phase 2b trial has similar outcomes to Phase 1b.Wasn't that only after the initial safety trial though with a handful of patients? Since then there had been no mention of tinnitus? Or did I miss some other news?
I just cannot fathom that they wouldn't say "hey you know what, during our trials we had a few folk who reported an improvement in their tinnitus."
How would that take away from anything or muddy the waters? Surely it would just be a positive signal. I really want there to be some hope and positive news from any of these drugs, I really do, but after speaking to a community of patients, i.e. Tinnitus Talk Podcast, prior to the trials and knowing how much some people need hope to cling onto holding back any sort of positive feedback would seem unusually cruel?
They state that Phase 2a could not confirm the effect of the drug for at least two reasons. One is the unusual effect of placebo and the other is multiple injections per week.This was the Phase 1b trial with a single dose of FX-322 that saw some patients with lower tinnitus level so hopefully the Phase 2b trial has similar outcomes to Phase 1b.
That was not in their data. It was anecdotal reports. Are we just making stuff up now?This was the Phase 1b trial with a single dose of FX-322 that saw some patients with lower tinnitus level so hopefully the Phase 2b trial has similar outcomes to Phase 1b.
Was TFI a survey item in Phase 1b?That was not in their data. It was anecdotal reports. Are we just making stuff up now?
I think some patients had improvements in Phase 1b so they decided to add it into Phase 2a but now they will redo the trial again with the single dose of FX-322 in Phase 2b which should give similar results to Phase 1b but with more patients.Was TFI a survey item in Phase 1b?
Since there was an anecdote about improving tinnitus, wasn't it adopted as a survey item in Phase 2a?
Originally, FX-322 is a drug whose purpose is not to improve tinnitus but to restore hearing.
I listened to most of it. More of the same. Focused on word recognition again. No mention of actual hearing improvement or tinnitus.40th Annual J.P. Morgan Healthcare Conference
Has anyone had a look at the video yet? Did they say anything that hasn't been stated yet such as more information about the severe hearing loss trial results or the current Phase 2b trial?
Word recognition improvement = actual hearing improvement.I listened to most of it. More of the same. Focused on word recognition again. No mention of actual hearing improvement or tinnitus.
Thought so. I did look at the presentation slides and with the severe hearing loss trial the information was the same as the last presentation slides for it.I listened to most of it. More of the same. Focused on word recognition again. No mention of actual hearing improvement or tinnitus.
Ah, keep telling yourself that. I have 45-50 WRS and I can't hear shit out of my left ear.Word recognition improvement = actual hearing improvement.